

**Advancing Drug Development for the Prevention and Treatment of Respiratory Syncytial
Virus Infections**

Marriott Marquis • Washington, DC
May 2, 2016

Participant List

Debra Birnkrant

Director, Division of Antiviral Products, U.S.
Food and Drug Administration

Wade S. Blair

Executive Director, Infectious Disease and
Vaccines, Merck

Michael Boeckh

Full Member, Vaccine and Infectious
Disease Division, Fred Hutchinson Cancer
Center
Professor of Medicine, University of
Washington

Jessica Burnell

Research Assistant, Duke-Margolis Center
for Health Policy

Jason Chien

Director, Clinical Research, Respiratory
Therapeutics Area, Gilead Sciences, Inc.

Greg Daniel

Deputy Director, Duke-Margolis Center for
Health Policy

Selena Daniels

Clinical Outcome Assessment Reviewer,
Division of Antiviral Products, U.S. Food and
Drug Administration

John DeVincenzo

Professor of Pediatrics & Professor of
Molecular Sciences, Microbiology,
Immunology, and Biochemistry, University
of Tennessee Center for Health Sciences

Filip Dubovsky

Vice-President, Clinical Biologics &
Therapeutic Area Head for Infectious
Disease and Vaccines,
MedImmune/AstraZeneca

Katie Greene

Research Associate, Duke-Margolis Center
for Health Policy

Tina Hartert

Professor of Medicine & Assistant Vice
Chancellor for Translational Science,
Vanderbilt University Medical Center

Frederick G. Hayden

Stuart S. Richardson Professor Emeritus of
Clinical Virology, University of Virginia
School of Medicine

Anna Maria Hibbs

Eliza Henry Barnes Chair in Neonatology,
UH Rainbow Babies and Children's Hospital
Associate Professor of Pediatrics, Case
Western Reserve University

Linda Lewis

Medical Team Leader, Division of Antiviral
Products, U.S. Food and Drug
Administration

Paolo Manzoni

Associate Professor of Pediatrics and Neonatology, S. Anna Hospital

Mark McClellan

Director, Duke-Margolis Center for Health Policy

H. Cody Meissner

Professor of Pediatrics, Tufts University School of Medicine
Chief, Division of Pediatric Infectious Disease, Tufts Medical Center

Veronica Miller

Executive Director, Forum for Collaborative HIV Research

Flor Munoz

Associate Professor of Pediatrics, Baylor College of Medicine

Jeffrey Murray

Deputy Director, Division of Antiviral Products, U.S. Food and Drug Administration

Anna Novotney-Barry

Vice President, Clinical Development, Aviragen Therapeutics

Katherine O'Brien

Professor, Department of International Health & Executive Director, International Vaccine Access Center, Johns Hopkins University School of Public Health

Giovanni Piedimonte

Chair, Pediatric Institute, Cleveland Clinic

Ramon Polo

Vice President and Head, Infectious Diseases and Global Public Health Regulatory Affairs, Janssen

Barbara Rath

Co-Founder and President, Vienna Vaccines Safety Initiative

Elizabeth Richardson

Research Associate, Duke-Margolis Center for Health Policy

Jeff Roberts

Medical Team Leader, Office of Vaccines Research and Review/Division of Vaccines and Related Product Applications, U.S. Food and Drug Administration

Sumita Roy-Ghanta

Adult and Pediatric Asthma, Allergy and Immunology Specialist, GlaxoSmithKline

Alan Shapiro

Medical Officer, Office of Translational Sciences/Office of Computational Science, U.S. Food and Drug Administration

Mary Singer

Medical Team Leader, Division of Antiviral Products, U.S. Food and Drug Administration

Stephen Toovey

Chief Medical Officer, Ark Biosciences

Prabha Viswanathan

Medical Officer, Division of Antiviral Products, U.S. Food and Drug Administration

Edward Walsh

Professor of Medicine, University of Rochester
Head of Infectious Diseases, Rochester General
Hospital

Robert Welliver, Sr.

Professor of Pediatrics & Section Chief,
Pediatric Infectious Diseases, University of
Oklahoma Health Sciences Center

James Witek

Global Respiratory Franchise Medical
Leader, Janssen